Tumor necrosis factor receptor-associated periodic syndrome p46l and bilateral amputation in diabetes

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2454-2455

  Quimby, Kim R ^a   Greenidge, Andre R ^a   Hennis, Anselm J ^a   Harrison, David K ^b   Landis, Robert Clive ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AMINO ACID SUBSTITUTION; AMPUTATION STUMP; ANKLE BRACHIAL INDEX; APOPTOSIS; BELOW KNEE AMPUTATION; CASE REPORT; DEBRIDEMENT; DIABETIC PATIENT; FEMALE; GANGRENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; HYPOXEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMYELITIS; OXYGEN SATURATION; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; WOUND HEALING;

ALLELES; AMPUTATION; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; FOOT; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; LEG; METATARSAL BONES; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; WOUND HEALING;

EID: 78549232671     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq227     Document Type: Letter

References (11)

1. Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005;7:1-18.
2. Landis RC, Evans BJ, Chaturvedi N, Haskard DO. Persistence of TNFα in diabetic wounds. Diabetologia 2010;53:1537-8.
3. Siqueira MF, Li J, Chehab L et al. Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1). Diabetologia 2010;53:378-88.
4. Harrison DK, Hawthorn IE. Amputation level viability in critical limb ischaemia: setting new standards. Adv Exp Med Biol 2005;566:325-31.
5. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
6. Nowlan ML, Drewe E, Bulsara N et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology 2006;45: 31-7.
7. Tchernitchko D, Chiminqgi M, Galactéros F et al. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005;13:513-5.
8. Hambleton IR, Jonnalagadda R, Davis CR, Fraser HS, Chaturvedi N, Hennis AJ. All-cause mortality after diabetes-related amputation in Barbados. A prospective case-control study. Diabetes Care 2009;32:306-7.
9. Yagnik DR, Evans BJ, Florey O, Mason JC, Landis RC, Haskard DO. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004;50:2273-80.
10. Drewe E, Powell RJ, McDermott EM. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007;46:1865-6.
11. Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006;27:494-508.